siRNA and Antibody Therapeutics for Anthrax Toxin Receptor Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anthrax infections, particularly inhalational anthrax, are inadequate as they rely on complex immunization schedules and 60-day antibiotic therapy, which becomes unreliable at later stages of infection when high levels of anthrax toxins are present, and there is a need for effective post-exposure prophylaxis against anthrax toxins.
Innovation Solution
The use of siRNAs and antibodies that target the cell surface expression of TEM8 and CMG2 proteins to block anthrax toxin binding, specifically administering siRNAs or antibodies to reduce anthrax toxin entry into cells, providing effective treatment for respiratory, cutaneous, and gastrointestinal anthrax infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complex immunization schedules and 60-day antibiotic therapy are used to treat anthrax infections, then some level of protection is achieved, but the treatment becomes unreliable at later stages of infection when high levels of anthrax toxins are present
Solution Approach 1:
The patent applies preliminary action by administering siRNA therapeutics that preemptively silence toxin receptor genes (tem8 and cmg2) before anthrax toxins can bind to and damage cells. This pre-silencing approach ensures protection is in place before toxin exposure reaches critical levels, making treatment reliable across all infection stages without requiring prolonged antibiotic therapy
2Object-affected harmful factors
If siRNA is administered to block anthrax toxin binding to cells, then anthrax toxin binding is significantly reduced and protection against cytotoxicity is achieved, but the mechanism requires gene silencing which may have off-target effects
Solution Approach 1:
The patent applies local quality by designing siRNA molecules with highly specific sequences that target only the tem8 and cmg2 toxin receptor genes. The siRNA design incorporates careful selection of target regions within these genes to ensure sequence specificity, minimizing off-target effects while achieving potent silencing of anthrax toxin receptors
Solution Approach 2:
The patent employs feedback mechanisms through controlled siRNA administration and monitoring of toxin receptor expression levels. The therapeutic approach allows for adjustment of siRNA dosing based on infection stage and toxin load, ensuring optimal suppression of toxin binding while maintaining safety through monitored gene silencing effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces anthrax toxin binding to cells, offering almost complete protection against cytotoxicity and death induced by anthrax lethal toxin, demonstrating potential as a life-saving therapy for both early and late-stage infections by silencing or blocking anthrax toxin receptors using RNAi technology or neutralizing antibodies.
Implementation Method 1
RNA interference-based therapeutic against anthrax; siRNA is provided to a subject that targets the cell surface expression of a TEM8 cell surface protein; siRNA is provided to a subject that targets the cell surface expression of a CMG2 cell surface protein
Implementation Method 2
an antibody is provided to a subject that blocks the interaction between the TEM8 cell surface protein and anthrax toxin; an antibody is provided to a subject that blocks the interaction between the CMG2 cell surface protein and anthrax toxin
Data Source
AI summary
The present invention includes siRNAs and antibodies that block the interaction between TEM8 and/or CMG2 cell surface proteins and anthrax toxin and methods of treating anthrax exposure with the same.